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ost-Thienopyridine
latelet Response,
ardiovascular Outcomes,
nd Personalized Therapy
n attendant Godot*
otirios Tsimikas, MD,† Gregor Leibundgut, MD†‡
a Jolla, California; and Basel, Switzerland
n Samuel Beckett’s tragicomedy “En attendant Godot” (1)
later translated to English from the original French version
y the author as “Waiting for Godot” [2]), Vladimir and
stragon wait excitedly by a tree on a country road for
odot, who is quite late in arriving with news of some
mportant matter that will significantly impact them. Even
hough they each claim to know him personally, in fact,
either knows him well at all. While anxiously waiting for
odot to arrive, they occupy themselves with multiple diver-
ions, some of which border on the absurd, including vaudeville
xhibitions and discussions on death, human existence, ethics,
hetoric, time, and money. This play is thought to prominently
epresent the Theater of the Absurd Movement, and its
ontent has led to different philosophical, political, psycholog-
cal, biblical, and other interpretations of the play’s meaning.
See page 648
The current unresolved status of the clinical utility of
ost-thienopyridine platelet response—and primarily clopi-
ogrel hyporesponsiveness—parallels some of the themes in
aiting for Godot by engendering different interpretations of
he data, controversy, and vibrant debate in how to currently
se such information, pending definitive trials. The main
ssues relate broadly to: 1) accurate measurement and
efinition of platelet hyporesponsiveness after thienopyri-
ine administration; 2) developing methodologies that are
ccurate, precise, reproducible, easy to use, and cost-
ffective; 3) defining when and in whom platelet hypore-
ponsiveness should be measured; 4) developing consensus
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †University of California, San Diego, La Jolla, California; and thet
University Hospital Basel, Basel, Switzerland. Dr. Tsimikas has served as consultant
o AstraZeneca.n appropriate criteria for platelet hyporesponsiveness that
redict optimal reduction of future events as well as bleed-
ng; 5) understanding the role of multiple genotypes, such as
YP2C19, that mediate poor response to clopidogrel; and 6)
efining the role of emerging P2Y12 receptor antagonists
hat have superior efficacy compared with clopidogrel.
The importance of inhibiting platelet function in patients
ith acute coronary syndromes (ACS) and after percutane-
us coronary intervention (PCI) takes on a supreme role
hen one considers that there are approximately 785,000
ew and 470,000 recurrent coronary events, 195,000 silent
yocardial infarctions, 795,000 strokes (2009 data), and
,313,000 PCI procedures in the U.S. (2006 data) (3).
ercutaneous coronary intervention carries an attendant 0.5%
o 2% risk of stent thrombosis over the first year, and for some
rug-eluting stents (DES) the risk might continue to increase
t a low but measurable rate over at least the next 5 years. Such
oncerns have led to the empiric recommendation that the
uration of dual antiplatelet therapy be increased to a mini-
um of 1 year after placement of a DES, pending randomized
ontrolled trials such as the DAPT (Dual Antiplatelet Study,
linical trial number: NCT00977938), which is testing 12
ersus 28 months of dual antiplatelet therapy. Therefore,
elevant information on optimal antiplatelet therapy from the
erspectives of appropriate drug, dosage, timing, and duration
ill be critical in improving clinical outcomes.
In that regard, in this issue of JACC: Cardiovascular
nterventions, French investigators represented by El Gha-
nudi et al. (4) document higher 9-month cardiovascular
ortality in a prospective registry in subjects undergoing
rgent and elective PCI with inadequate response to clopi-
ogrel, measured by the vasodilator-stimulated phospho-
rotein test (VASP). On the basis of the VASP platelet
eactivity index (PRI) of 61% as determined by receiver
perating characteristic curve analysis, 40% of patients were
ow-responders to clopidogrel. The use of DES, impaired
enal function, high C-reactive protein, and low responsive-
ess to clopidogrel were all predictive of cardiovascular
ortality. This study adds to the rapidly growing observa-
ional study database on post-clopidogrel platelet hypore-
ponsiveness and clinical outcomes. Although there is cur-
ently no consensus regarding the appropriate methodology
nd criteria that define on-treatment platelet hyporespon-
iveness, several studies using a variety of assays have
onsistently shown that inadequate response to clopidogrel
redicts risk of future major adverse cardiac events in
atients undergoing PCI (Table 1).
Definitive outcomes data do not yet exist showing that
odifying therapy on the basis of a platelet function test
eads to improved outcomes. However, the recognition of
he highly variable response of clopidogrel, the fact that 20%
o 40% of patients are hyporesponsive, and the associated
isk this entails is appropriately driving further research in
he utility of platelet function testing. Clopidogrel is a
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658rodrug that is converted to active metabolites by the
ytochrome system in the liver, and particularly CYP2C19,
hich then bind irreversibly to the P2Y12 platelet receptor,
ltimately leading to inhibition of platelet aggregation.
here are several tests that measure platelet responsiveness
o thienopyridines (5). Light transmission aggregometry
LTA) measures increased light transmission in response to
latelet aggregation by adenosine diphosphate (ADP) act-
ng on the P2Y12 receptor and is the gold standard but
equires a dedicated clinical laboratory with trained techni-
ians. The VerifyNow (Accumetrics, San Diego, California)
ystem is a bedside test that measures enhanced light trans-
ission after agglutination of fibrinogen-coated beads in re-
ponse to the thrombin receptor agonist iso-TRAP and to
rostaglandin E1 (PGE1) and ADP. The data are presented as
bsolute P2Y12 reaction units and as a percentage inhibition of
he basal (iso-TRAP) and ADP induced values. In the VASP
ethod, phosphorylated VASP is detected with fluorescently
abeled anti–P-VASP antibodies with flow cytometry. Resting
latelet reactivity is established in response to PGE1, and
ctivated platelet reactivity is established in response to PGE1
lus ADP. The PRI is then expressed as a mean percentage of
latelet reactivity. Lower PRI values are associated with higher
ntiplatelet efficacy (6).
Recently, the POPULAR (Do Platelet Function Assays
Table 1. Assessment of Platelet Reactivity in Clinical Outcomes in Patient
First Author Year
(Ref. #) Study Population Clopidogrel Loading Dose
El Ghannudi et al.
2010 (4)
Urgent and elective PCI
(n  461)
300/600 mg V
Breet et al. 2010 (7) Elective PCI (n  1,069) 75 mg/day therapy for
5 days or a loading
dose of 300 mg 24 h
before PCI or 600 mg
4 h before PCI
L
Migliorini et al.
2009 (12)
Unprotected left main
disease (n  215)
600 mg 12 h prior to PCI L
Marcucci et al.
2009 (13)
PCI for ACS (n  683) 600 mg prior to PCI V
Price et al. 2008 (14) Elective PCI (n  380) 600 mg 12 h prior to PCI V
Bonello et al.
2007 (15)
Elective PCI (n  144) 300 mg 24 h prior to PCI V
Bliden et al.
2007 (16)
Elective PCI (n  100) Chronic 75 mg 1 month,
no loading dose
L
Gurbel et al.
2005 (17)
Elective PCI (n  192) 300/600 mg post-PCI L
Matetzky et al.
2004 (18)
PCI for STEMI (n  60) 300 mg post-PCI L
Impact-R (DiaMed, Cressier surMorat, Switzerland); Innovance (Dade Behring,Marburg, Germany); P
ACS  acute coronary syndrome; CV  cardiovascular; LTA  light transmission aggregometry (5
PCI percutaneous coronary intervention; PRI platelet reactivity index; PRU platelet reactivity
tography; TVR target vessel revascularization; VASP vasodilator-stimulated phosphoprotein phredict Clinical Outcomes in Clopidogrel-Pretreated Patients bndergoing Elective PCI?) study (7) has overcome several of
he limitations of prior studies evaluating clopidogrel hypore-
ponsiveness, including small sample size, low event rates,
ifferent cutoffs for hyporesponsiveness, and lack of compari-
on of different platelet function tests, by performing a head-
o-head comparison of 6 platelet function tests, determining
utoff values for high on-treatment platelet reactivity on the
asis of receiver-operator characteristic curves and then evalu-
ting their relationship to major adverse cardiac events and
hrombolysis In Myocardial Infarction bleeding. They docu-
ented that only the LTA, Plateletworks (Helena Laborato-
ies Corp., Beaumont, Texas), and VerifyNow (Accumetrics)
2Y12 tests predicted clinical outcomes in patients pre-treated
ith clopidogrel undergoing elective PCI. Interestingly, it
eemed that the aggregation tests were better predictors of
vents than the sheer-based tests. However, all tests had low
ositive predictive value after taking into account conventional
isk factors and procedural variables, and none predicted
leeding. Further studies are needed to assess their predictive
alue in higher-risk subsets such as ST-segment elevation
yocardial infarction, ACS, and complex coronary anatomy
nd interventions.
Because clopidogrel is converted to its active metabolite
y the hepatic cytochrome enzymes and because several
oss-of-function single-nucleotide polymorphisms have
h ACS or PCI With >6-Month Follow-Up
latelet Function Test Follow-Up (Months) End Point Prediction
RI 61%) 9 PRI 61% predicted
reduced total and CV
mortality and ST
, VerifyNow, Plateletworks,
CT-R, PFA-100, Innovance
12 MACE predicted by LTA,
VerifyNow, Plateletworks
19.3 High residual platelet
reactivity (70% by
ADP) predicted cardiac
death and DES ST
ow 12 PRU 240 predicted death
and nonfatal MI
ow 6 PRU 235 predicted MACE
6 PRI 50% predicted
reduced MACE
EG 12 Reduced MACE
TEG 6 Reduced MACE
, CPA 6 Reduced MACE
orks (Helena Laboratories Corp., Beaumont, Texas); VerifyNow (Accumetrics, SanDiego, California).
 amount adenosine diphosphate [ADP] in mg/dl used); MACE  major adverse cardiac events;
ST stent thrombosis; STEMI ST-segment elevation myocardial infarction; TEG thromboelas-
ylation.s Wit
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659ogrel, a debate has emerged as to whether universal
enotyping would provide enhanced predictive value. How-
ver, individual or even a collection of relevant single-
ucleotide polymorphisms explain only a modest amount of
he variability in clopidogrel response as measured by LTA
8). Additional demographic (obesity, ACS, diabetes), en-
ironmental (drugs, noncompliance), biochemical (high fi-
rinogen levels [9]), procedural (unrecognized dissections
nd poor stent apposition), and other parameters ultimately
ediate clinical events. Finally, most subjects with clopi-
ogrel hyporesponsiveness will not have a future event,
hich provides an imperative to primarily screen the
ighest-risk patients. By contrast, with the complexity of
he cytochrome P450 system, designing a genotype-driven
linical trial where patients are randomized to different
herapies on the basis of loss of function alleles will be
hallenging. Therefore, it remains to be determined how
his aspect of “personalized” therapy will evolve in the near
uture.
Do we even need genotyping or phenotyping, in the form of
latelet function tests, with the approval of prasugrel and, in
he future, ticagrelor and other P2Y12 antagonists, which have
ore potent antiplatelet effects and very low incidence of
latelet hyporesponsiveness (10)? Although prasugrel is asso-
iated with better efficacy and also more bleeding, ticagrelor
emonstrated reduced cardiovascular mortality with similar
leeding rates (11). With clopidogrel becoming available as a
eneric drug soon, cost issues might ultimately drive the debate
bout when and if to genotype or measure platelet function.
Unlike in Waiting for Godot (2) where Godot does not
ltimately appear and Vladimir and Estragon do not find
ut the “news”, randomized trials are underway to help
linicians individualize treatment of antiplatelet therapies.
hese trials will measure platelet responsiveness after clo-
idogrel and randomize patients either to standard therapy
ersus a higher dose of clopidogrel (GRAVITAS [Gauging
esponsiveness With A VerifyNow Assay-Impact On
hrombosis And Safety] [NCT00645918], DANTE [Dual
ntiplatelet Therapy Tailored on the Extent of Platelet
nhibition] [NCT00774475], and ARCTIC [Double Ran-
omization of a Monitoring Adjusted Antiplatelet Treatment
ersus a Common Antiplatelet Treatment for DES Im-
lantation, and Interruption Versus Continuation of Dou-
le Antiplatelet Therapy] [NCT00827411]) or to prasugrel
TRIGGER-PCI [Testing Platelet Reactivity In Patients Under-
oing Elective Stent Placement on Clopidogrel to Guide Alter-
ative Therapy With Prasugrel] [NCT00910299]). Ultimately,
or selected patients, particularly those at high risk of throm-
otic events, it is possible that data derived from platelet
unction testing might be useful in improving patient out-
omes. The resolution of these issues in the next few years will
ltimately allow clinicians to effectively individualize and pre-
cribe optimal antiplatelet therapies in patients with ACS and
articularly those undergoing PCI. teprint requests and correspondence: Dr. Sotirios Tsimikas,
ascular Medicine Program, University of California, San Diego,
500 Gilman Drive, La Jolla, California 92093-0682. E-mail:
tsimikas@ucsd.edu.
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